The diagnostic performance of 2 enzyme-linked immunosorbent assays (gX-T, gX-H) for antibodies to pseudorabies virus (PRV) glycoprotein X (gX) were evaluated using 311 serum samples from a nonvaccinated quarantined herd. When the standardized virus neutralization (VN) test, which uses the Shope strain (VN Shope), was used as the comparative diagnostic standard, the gX-T test had a 7% false-negative rate and a 52% false-positive rate, and the gX-H test had a 19% false-negative rate and a 19% false-positive rate. When the VN test with a Bartha recombinant strain (VN Bartha gIII Ka ) was used as the diagnostic standard, the gX-T test had a 9% false-negative rate and a 26% false-positive rate, and the gX-H test had a 24% falsenegative rate and a 11% false-positive rate. Thus, the gX-T test was more sensitive and the gX-H test was more specific. Additional diagnostic tests on 79 serum samples from a noninfected herd did not produce false positives for the gX-H test, but there was an 8% false-positive rate for the gX-T test. Previous studies from our laboratory have demonstrated that VN Bartha gIII Ka has higher sensitivity than VN Shope, without losing specificity, and thus is a better comparative diagnostic standard. When adding a suspect range to the gX-T test, using the same criteria as the suspect range for the gX-H test, the false-positive rate of the gX-T test was reduced to 5% when evaluated versus VN Bartha gIII Ka in the infected herd and to 1% for the PRV-negative herd. However, 18% of the positive samples were classified as suspect (vs. 8% for the gX-H test). In PRV eradication programs, the cost of false negatives is greater than the cost of false positives; thus, the gX-T diagnostic used in this study is of greater diagnostic value.
The serum virus neutralization (VN) test 6 has been the standard test used most frequently in the United States for the serologic diagnosis of pseudorabies virus (PRV) infection in swine. However, the VN test cannot differentiate between antibodies to field and vaccine strains of the virus. This limitation is important now that vaccination plays a central role in pseudorabies eradication programs. Recently, PRV vaccines have been altered by the deletion of genes for specific glycoproteins. Concurrently, differential tests have been developed that detect antibodies to these glycoproteins, thus allowing for differentiation between field and vaccine strains of PRV. By the end of 1990, the USDA had approved 3 vaccines a,b,c for use in establishing qualified negative herd status because of the availability of differential serologic tests. 8, 9 Success in eradication of PRV is dependent upon the accuracy of serologic diagnostic tests. In a study involving experimental infection with various PRV vaccine strains, 16 the VN test had lower sensitivity than the latex agglutination test (LAT), d particularly during the first month following infection. The standard VN test uses the Shope strain of PRV 6 (VN Shope). A recent study 14 examining the effect of PRV test strain on the results of VN tests demonstrated that the sensitivity of the VN test can be improved significantly by using strains other than Shope. In particular, use of a recombinant strain, Bartha gIII Ka (the gIII gene in the parental Bartha strain has been replaced by its homologue from the Kaplan strain), 11 resulted in VN titers 4-6 times higher than for the Shope strain. With respect to vaccine differential tests, in a study 2 of pigs naturally or experimentally infected with PRV or given a wild type virus vaccine, a differential ELISA test e for detection of antibodies to glycoprotein X (gX) identified 82% (116/141) of the positives diagnosed by a nondifferential screening ELISA. f Similar results were obtained in another study 15 using the same differential test to evaluate 330 feral swine sera; there was 87% sensitivity when compared with the standard VN Shope test as a diagnostic standard and 79% sensitivity when compared with the LAT. In contrast, in a study 13 with experimental infection using virulent PRV strains, close to 100% sensitivity was achieved for this gX test. The current study evaluates the relative sensitivity and specificity of the 2 USDA-licensed enzyme-linked immunosorbent assay (ELISA) differential tests e,g to detect anti-gX antibodies as compared with each of the 2 VN tests as diagnostic standards. Results are eval- 
Materials and methods
Two herds were sampled in this study. One herd was part of the USDA sponsored Large Herd Pseudorabies Clean-up Project in Illinois. 5 This herd, which had been quarantined since 1978, had not used a PRV vaccine previously. There had been no clinical signs of PRV infection since the initial outbreak. Three hundred eleven serum samples (149 sows and 162 finishing pigs >70 kg) were obtained from this herd. Testing for antibodies to PRV was conducted at the Illinois Bureau of Animal Disease Laboratory (Galesburg, IL); each sample was assayed by both the VN test (standard test using the Shope strain) and 2 differential ELISA tests for antibodies to glycoprotein X (gX-T, g gX-H e ). Additional diagnostic testing was conducted in research laboratories at the University of Illinois College of Veterinary Medicine. The VN test was performed again, using the recombinant strain Bartha gIII Ka as the test virus. A single-dilution indirect solid-phase radioimmunoassay (RIA) for detecting anti-PRV IgG antibodies was also performed. 17 This RIA is approximately 128 times more sensitive than the standard VN Shope test.
An additional 79 serum samples obtained from a PRVfree nonvaccinated herd were tested for anti-PRV antibodies using the VN Shope test and for antibodies to PRV glycoprotein X using the gX-T and gX-H tests. The VN and gX-T tests were conducted at the Illinois Bureau of Animal Disease Laboratory at Centralia, and the gX-H test was conducted at the Galesburg Laboratory.
A titer of 24 indicates a positive VN test. For the gX tests, the cutoff criteria for diagnosis set by the manufacturer were utilized. A sample : negative ELISA optical density ratio (S/N ratio) of greater than 0.7 is a negative result for both tests. For the gX-H test, samples with an S/N ratio of 0.6-0.7 are classified as suspect, and samples with an S/N ratio of <0.6 are classified as positive. For the gX-T test, samples with an S/N ratio of <0.7 are classified as positive; there is no suspect range. For comparison and interpretation, the 0.6-0.7 positive range of the gX-T test is listed below as a separate category.
The gX differential tests were evaluated alternately against the VN Shope test and the VN Bartha gIII Ka test as the comparative diagnostic standard on the basis of the following criteria. Sensitivity is the percentage of VN positives classified as positive by the gX test. Specificity is the percentage of VN negatives classified as negative by the gX test. The false-negative rate is the percentage of VN positives classified as negative by the gX test. The false-positive rate is the percentage of VN negatives classified as positive by the gX test. Because the VN test is not 100% accurate in PRV diagnosis, the sensitivity and specificity estimates and falsepositive and -negative rates are only relative to the VN test. Agreement between diagnostic tests was quantified using the kappa statistic (K), which corrects for chance agreement due to unequal distribution of positives and negatives. 1 
Results
The performance of the gX differential tests versus VN Shope as the diagnostic standard is shown in Table  1 . The sensitivity of the gX-T test was 93%, and its specificity was 48%. There was a 52% false-positive rate and a 7% false-negative rate. Agreement between the VN Shope and gX-T tests was moderate (K = 0.41). Figure 1 indicates that there was high variation in the ELISA S/N ratio scores at VN titers up to 64, with false negatives produced up to a titer of 16. The sensitivity of the gX-H test was 72%, and the specificity was 81%. The false-positive and false-negative rates were both 19%. Eight percent of the gX-H test results were suspect. Agreement between the VN Shope and gX-H tests was also moderate (K = 0.43). Figure 2 shows that the gX-H test S/N ratio was also highly variable at each VN Shope titer, with false negatives produced up to a titer of 128. The performance of the gX differential tests versus VN Bartha gIII Ka as the diagnostic standard is shown in Table 2 . The sensitivity of the gX-T test was 91%, and its specificity was 74%. The false-positive rate was 26% and the falsenegative rate was 9%. Agreement between tests was moderate (K = 0.43). Figure 3 indicates that most of the false positives were in the S/N ratio range of 0.6-0.7. False negatives were produced up to a titer of 128. The sensitivity of the gX-H test versus VN Bartha gIII Ka was 68%, and its specificity was 83%. The falsenegative rate was 24%, and the false-positive rate was 11%. There was low agreement between the VN Bartha gIII Ka and gX-H tests (K = 0.24). Figure 4 shows that the gX-H test produced false negatives up to a VN Bartha gIII Ka titer of 256. Table 3 shows the agreement between diagnostic tests of the same type. VN Bartha gIII Ka agreed moderately with the VN Shope (K = 0.56); VN Bartha gIII Ka clas- sified more sera as positive, and 8.8% of the VN Bartha gIII Ka positives were classified as negative by VN Shope. VN Bartha gIII Ka agreed more highly with the PRV RIA (K = 0.78; 95% C.I.: 0.66-0.89) than did VN Shope (K = 0.62; 95% C.I.: 0.51-0.73), although there was good agreement for both VN tests. There was low agreement between the gX tests (K = 0.35); 65% (51/ 78) of the gX-H negatives were classified as positive by the gX-T test. The gX-T test had moderate agreement with the PRV RIA (K = 0.45; 95% C.I.: 0.34-0.57), and the gX-H test had low agreement with the RIA (K = 0.29; 95% C.I.: 0.20-0.38).
All VN Shope and gX-H test results from the PRVfree herd were negative. However, the gX-T test produced 6 positives, for an 8% false-positive rate (specificity = 92%). Figure 5 shows the distribution of S/N ratio scores for the differential tests. Five of the 6 gX-T test positives had S/N ratios in the 0.6-0.7 range.
Discussion
The relative sensitivity and specificity of a diagnostic test is a function of laboratory conditions under which chronic, latent phase for PRV). In our study of a herd in the latent phase of PRV infection, the gX-T differential test had high sensitivity (93%) but low specificity (48%) when evaluated against the standardized VN Shope test. The gX-H test had better specificity (8 1%) but lower sensitivity (7 1%). Previous studies of the diagnostic performance of the gX-H test have obtained better results. In a study 15 of feral pigs, which were presumably chronically infected, the gX-H test obtained higher sensitivity (87%) and specificity (98%) versus VN Shope (a titer of ≥4 as positive) than in the current study. In another study 2 using a mixed sample of sera (naturally and experimentally infected and vaccinated), the gX-H test achieved similar sensitivity (82%) versus a screening ELISA as a diagnostic standard; the false-positive rate for samples from negative herds was <1%. In a study 13 using experimental in- Table 3 . Agreement between 2 virus neutralization (VN) tests and between 2 gX differential tests for pseudorabies virus. fection as the diagnostic standard, the gX-H test had close to 100% sensitivity during the acute phase of infection. These previous laboratory-controlled results may represent the potential sensitivity of the gX-H test. The current study evaluates the diagnostic performance of the gX tests at a state diagnostic laboratory for a herd in the latent phase of infection (a characteristic of herds near quarantine release), which may more accurately represent the conditions under which such testing results lead to decision making in pseudorabies eradication programs.
Glycoprotein X may either be not as consistently expressed or not as immunogenic as gI or gIII. 15 An experimental infection study 10 found that anti-gX antibodies do not persist as long as the overall PRV antibody response. In contrast, another study 2 using the gX-H test was able to detect anti-gX antibodies up to 1 year after experimental infection with the PRV Shope strain. Although these conflicting results leave issues unresolved, the sensitivity of a gX ELISA test for detecting PRV may be reduced after the initial infection. The performance of gX tests in identifying naturally infected animals must also be evaluated against an appropriate diagnostic standard. Previous results 16 indicate that the LAT has better sensitivity than the VN Shope assay during the acute infection phase. Our laboratory 14 found that the VN Bartha gIII Ka test produced titers over 4-6 times higher than did the VN Shope test; 24 sera diagnosed as negative both by the VN Shope test and the highly sensitive PRV RIA used in that study were also classified as negative by the VN Bartha gIII Ka test. Thus, the VN Bartha gIII Ka test has increased sensitivity without loss of specificity. Furthermore, the higher agreement with the PRV RIA for the VN Bartha gIII Ka test in the current study also suggests that the VN Bartha gIII Ka test is more sensitive than the VN Shope test, the standardized PRV VN assay. Thus, in evaluating the gX differential tests, the VN Bartha gIII Ka test appears to be a better diagnostic standard.
When evaluated against the VN Bartha gIII Ka test as a diagnostic standard, the false-positive rate of the gX-T test drops from 52% to 26%, whereas the false-negative rate of the gX-H test rises from 19% to 24%. The falsenegative rate of the gX-T test (9%) and the false-positive rate of the gX-H test (11%) are both approximately 10%. Thus, in the testing for the study sample, there was an equal trade-off in false-positive and falsenegative rates; the gX-T test diagnoses too many positives and the gX-H diagnoses too many negatives when the manufacturers' cutoff points are used.
The gX-T test does not have a suspect range. However, if S/N ratio values of 0.6-0.7 are classified as suspect (as they are in the gX-H test), the false-positive rate of the gX-T test with VN Bartha gIII Ka as a diagnostic standard (Table 2) improves to 5% (1/19), although the sensitivity drops to 74% (212/288) because 50 VN Bartha gIII Ka positives are now classified as suspect. For the negative herd, 5 of the 6 gX-T test positives were in the 0.6-0.7 range (Fig. 5) ; reclassifying these as suspect would lower the false-positive rate to 1%. Using the suspect range for the gX-T test would give this test a lower false-positive rate (5% vs. 11%) and false-negative rate (9% vs. 24%) than the gX-H test but a greater proportion of suspects (18% vs. 8%). The suspect classification can be manageable if the test can be repeated, the cost is low, and waiting for a definitive diagnosis does not pose an additional disease threat. These conditions are usually satisfied in serologic testing for latent pseudorabies infection.
There may be limits to the agreement among PRV diagnostic tests. The VN assay tests for antibodies only to the neutralizing subset of viral antigens. The standard (nondifferential) ELISA and the RIA test a broader set of all expressed proteins that bind antibody with the required affinity. The gX differential ELISAs detect all antibodies to this single protein. These different assays may correlate but need not if antibody subsets to the various proteins do not develop at the same rate. A lack of correlation of a gX test with a standard ELISAs and lower correlation of RIA and VN titer during the first weeks after infection (E. C. Hahn, unpublished) indicate the potential problem. If the tests do not correlate, different standards would exist for release from quarantine for vaccinated and nonvaccinated herds. If vaccine differential tests produce false positives, the increased duration of quarantine must be added to the cost equation.
The relative cost of false-positive and false-negative diagnosis for disease control can be evaluated by considering the conditions under which the tests are utilized. The differential tests evaluated in this study are used for herds that have been vaccinated with a gX-deleted vaccine. In Illinois, these herds have already been quarantined for PRV infection, most likely as a result of VN testing. Vaccination should increase PRV antibody levels and reduce viral activity, PRV clinical signs, and virus excretion and transmission. Release from quarantine occurs when the seroprevalence is zero. As prevalence decreases, a greater proportion of test positives will be false positives. Thus, a test that has a high false-positive rate may keep a herd quarantined for a longer period of time. However, with a small number of positives, additional confirmatory testing of these samples can be conducted using diagnostics with equal or greater sensitivity and high specificity. For example, if it is feasible to sacrifice a few of these positive animals, a polymerase chain reaction (PCR) technique for PRV may satisfy these conditions. Such a technique is currently in use at the National Veterinary Services laboratory (Ames, IA) for detection of the PRV gp50 gene. 4 However, the gp50 PCR will not differentiate between wild-type and vaccine virus because this essential viral gene has not been deleted from vaccine virus.
False negatives pose a different problem. Release from quarantine due to failure to detect PRV-infected animals can result in movement of PRV-infected feeder pigs and breeding stock to other herds. Adjustments can be made for highly specific tests with low sensitivity by increasing sample size, which increases the probability of finding at least 1 positive in a herd. 12 Because a single positive animal is sufficient to maintain a quarantine, this approach would appear to decrease the probability of falsely diagnosing a herd as free of infection, assuming however, that a false di-agnosis is independent of herd disease conditions. For is no longer apparent. Thus, changes in the gX-T test, PRV in the latent infection/low prevalence stage, an-leading to its withdrawal, appear to have been mistibody levels may be low for all animals. Thus, the guided. same condition of low antibody levels that leads to a false-negative diagnosis in 1 animal may also exist for
Sources and manufacturers other animals tested, and additional false-negative tests will result. For PRV in the latent phase of infection, a. Tolvid®, The Upjohn Co., Kalamazoo, MI. there will not be clinical signs to provide additional year (perhaps in response to a perceived poor specificity). In our follow-up serologic testing of the herd analyzed here (which had been vaccinated subsequently with a gX-vaccine a ), a remarkable change in PRV diagnosis using the gX-T test occurred. Of the 15 sows that tested positive (S/N ratio < 0.6) in December 1990, 10 (67%) were negative, 1 (7%) was suspect (0.6 5 S/N ratio ≤ 0.7), and 4 (27%) remained positive in February 1991. All 16 sows that had a suspect diagnosis in December 1990 were diagnosed as negative in February 1991. None of the 10 seronegative sows mize the unnecessary quarantine of noninfected herds.
from the first sampling tested positive in the subsequent sample, although this seroconversion was possible in this infected herd. The irony in these results is that the May 1990 version of the gX-T assay ap-Use of the gX-T test in state diagnostic laboratories parently had adequate sensitivity and (with the addi-has been suspended (as of June 1991), and this diagtion of a suspect range) high specificity, although there was an apparent problem with the high percentage of nostic assay is being revised to increase its sensitivity. 3 suspects. Preception of low specificity of the gX-T test around this time may have been due to comparison with the VN Shope, a diagnostic standard with some-Our May 1990 gX-T testing indicated >90% sensitivwhat limited sensitivity. With a more sensitive diagnostic standard (such as the VN Bartha gIII Ka ) and the addition of a suspect range, the low specificity problem ity, higher than the gX-H test in our study. Some state laboratories are now replacing the gX-T test with the gX-H test or are running both tests. 3 Data collected in our Large Herd Clean-up Project indicate that the sensitivity of the gX-T test has decreased over the last parison of differential diagnostic tests to detect antibodies to antigens based on ELISA, serum virus neutralization, and latex pseudorabies glycoproteins gX, gI, and gIII in naturally infected agglutination tests. J Vet Diagn Invest 2:29-34. feral pigs. J Vet Diagn Invest 3:344-345.
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